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AN ANALYSIS OF FINANCING INNOVATION AND COMMERCIALIZATION IN 
CANADA’S FUNCTIONAL FOOD AND NUTRACEUTICAL SECTOR 
 
ABSTRACT 
Growing consumer interest in functional foods and nutraceuticals has been seen as a significant 
business opportunity for the agri-food sector.  Many of the new firms in this sector are small and 
medium sized enterprises (SMEs).  These SMEs often face difficulties in obtaining financing for 
their functional food and nutraceutical innovation and commercialization activities.  We develop and 
implement two models to show what factors affect a firm’s decision to seek external financing and 
the level of financing obtained.  Firm size, being privately held and engaging in contractual 
arrangements, have negative impacts on the likelihood of a firm seeking external funding, while 
firms which are intensively involved in the functional food and nutraceutical sector, with greater 
prospects for business expansion and/or are involved in partnerships are more likely to seek 
external financing.  Larger firms and those involved in functional food and nutraceutical research 
and development receive a greater amount of capital when they decided to raise capital.  However, 
firms focused on functional foods and nutraceuticals, as opposed to more diversified firms, and 
those involved in product development and concept scale-up receive less capital.  Our findings 
highlight the importance of public support in addressing the capital requirements of functional food 
and nutraceutical firms and underscore the considerable burden in this respect borne by smaller 
sized firms.   
Keywords: Functional foods; Nutraceuticals, Economics, Finance, SMEs   2
AN ANALYSIS OF FINANCING INNOVATION AND COMMERCIALIZATION IN 
CANADA’S FUNCTIONAL FOOD AND NUTRACEUTICAL SECTOR 
 
Recent consumer research in Canada suggests that consumers are increasingly aware of functional 
foods and nutraceuticals and value the potential health benefits associated with a range of functional 
ingredients (West et al. 2002; AAFC 2004; Health Canada 2005).  Indeed, there is evidence that 
consumers have moved beyond awareness; a growing proportion of consumers have tried functional 
foods and nutraceuticals, with a significant minority using such products on a regular basis.  These 
trends are not unique to Canada, with similar developments being observed in many industrialized 
country markets.  Market research data for the period 2002 to 2004 (AC Nielson 2004) suggest that, 
among the seven food and beverage product categories with the greatest rates of growth in sales, six 
categories were health-promoting products.  Not unsurprising, functional foods and nutraceuticals 
have been recognized as a significant business opportunity for the agri-food sector and, at the same 
time, a potentially effective means to promote health and well-being in the population and reduce 
health-related costs (Malla et al. 2005). 
  Recognizing the market potential for functional foods and nutraceuticals, a number of firms 
in Canada have begun to capitalize on the opportunities trends in consumer demand present.  While 
data is somewhat limited, it is estimated that the Canadian nutrition sector grew eight percent over 
the period 2002 and 2003, with an estimated value of nearly US$5 billion in 2003 (Nutrition 
Business Journal 2004).  The majority of firms in the Canadian functional food and nutraceutical 
sector are small and medium-sized enterprises (SMEs); a 2003 survey (on which the analysis 
reported below is based) of firms engaged in this sector found that around 50 percent of firms had 
less than 20 employees, while  85 percent had less than 100 employees.  The key focus of this paper 
is the extent to which firms face difficulties in exploiting opportunities in the functional food and   3
nutraceutical sector predominantly due to problems accessing finance and, in turn, the extent to 
which this relates to the predominance of SMEs. 
  Kamien and Schwartz (1978, p. 252) observe: “among the leading characteristics commonly 
associated with industrial research and development, one of the most prominent is the virtual 
necessity for it to be financed internally from a firm’s current profits and accumulated funds.”  This 
reliance on self-financing often arises as financiers and investors ration capital to minimize exposure 
to risk, or to seek out a higher risk-adjusted rate of return.  Problems accessing capital are a 
predominant obstacle for SMEs seeking to finance their innovation activities through sources 
external to the firm.  Indeed, the literature suggests a disparity between the rate of return required by 
entrepreneurs investing their own funds and that required by external investors (Hall 2005).  A 
variety of reasons for the expectation of higher rates of return among external financiers are 
documented in the literature.  Arrow (1962) notes the moral hazard problems associated with 
external financing of risky innovative activities, whereby a detailed account of such activities are not 
provided to the external financier due to the risk of leaking confidential proprietary information.  
Thus, the reluctance of innovative firms to reveal their ideas to financial markets (because of the 
non-rival nature of such information) reduces the quality of the signal the firm can deliver about a 
potential project (Bhattacharya and Ritter 1983).  It is argued, therefore, that due to these 
informational asymmetries and moral hazard problems, innovative activities are difficult to finance 
in a freely-competitive market (Nelson 1959; Arrow 1962; Trester 1994; Gompers 2001).   
  An added ramification to the signalling problem associated with raising capital for innovative 
activities is the significant informational rent created by the highly regulated nature of the functional 
food and nutraceutical sector, especially in the case of novel foods.  Scientific uncertainty regarding 
the efficacy of functional foods and nutraceuticals can aggravate informational frictions between the 
lender and the borrower.  Further, there may be risks associated with the protracted process of   4
approval of novel foods, especially where this process is not well understand and developed, such as 
in Canada.  Innovative activities of this kind are hard to monitor due to information asymmetries 
and there is a significant potential for the misalignment of interests between the innovating firm and 
providers of external financing. 
  In addition to the problems of information asymmetry and moral hazard associated with 
raising capital for research and development, there is frequently a lack of collateral, especially among 
SMEs, because of the dominant role of human capital (in the form of highly educated and skilled 
scientists) in the innovation process.  Limited collateral may constrain the ability of innovative firms, 
and especially SMEs, to borrow, presenting perhaps a prima facae case for government to act as a 
source of financing.  Addressing such difficulties, however, requires a better understanding of the 
factors that mitigate a firm’s ability to undertake innovation, specifically in the current context of 
functional food and nutraceutical development and commercialization.  An unknown in this regard 
is the capacity of firms in the functional food and nutraceutical sector to respond to the emerging 
demand for such products and the constraints that hinder their efforts. 
  Development and commercialization of functional foods and nutraceuticals share many of 
the characteristics of advanced food innovation, but also have certain unique attributes, in particular 
where these are the product of biotechnology.  Thus, for example, specific functional foods and 
nutraceuticals may not have been produced and consumed in Canada previously and are subject to 
prior regulatory approval as novel products (Health Canada 2005).  Further, the ability to make 
health-related claims on functional foods and nutraceuticals is strictly controlled and, within the 
limits of current regulations, is dependent on the availability of scientific evidence demonstrating 
appreciable health benefits.  Broadly, these regulatory processes influence the nature of product 
development and commercialization, enhancing levels of capital intensiveness, including both 
physical resources and human capital, and having an effect on the level of risk associated with   5
innovation.  Regulatory differences between Canada and other countries with respect to health 
claims and approval processes for functional foods and nutraceuticals can further exacerbate the 
problems experienced by innovative firms in raising external finance, such that capital rationing is 
the norm rather than the exception. 
  The current paper seeks to enhance understanding of the ability of firms in the functional 
food and nutraceutical sector in Canada to raise capital in pursuit of product development and 
commercialization.   Specifically, it explores the characteristics of firms that seek external financing 
and those that are successful in this pursuit, highlighting those factors that tend to facilitate or 
impede access to capital and the amount of financing that is raised.  Data are obtained from the 
Functional Food and Nutraceutical Survey (FFNS) undertaken by Statistics Canada in 2003.  This 
survey provides relatively detailed information on the nature of firms engaged in the functional food 
and nutraceutical sector.  Using these data, the analysis below presents the first in-depth assessment 
of the role of external financing in the functional food and nutraceutical sector, and indeed advanced 
food innovation more generally, not only in Canada but internationally. 
 
Conceptual Framework 
Many factors influence of a firm's propensity to seek capital as a means to finance their innovation 
and commercialization activities (Hall 2002, 2005).  These multi-factorial influences create challenges 
when attempting to measure the role of a firm or sector-specific characteristic.  Indeed, we have a 
rather imprecise understanding of the direction and magnitude of the impact a particular 
characteristic has on a firm’s propensity to raise capital, both generally and in the specific context of 
the functional food and nutraceutical sector.  In this context, there is scope to undertake empirical 
analysis in order to better understand the determinants of financing for innovation and   6
commercialization.  Before doing so, however, we develop a conceptual framework to help shape 
our understanding of behaviour of firms seeking capital. 
    Much of the early conceptual work on firm-level capital seeking focused on deriving 
optimality rules to guide what factors shape the level of investment a firm requires.  This work was 
often undertaken in the context of investment in capital stock in neoclassical growth models (see 
Aghion and Howitt 1997), or investment in research and development/innovation in decision or 
game theoretic settings (see, for example, Kamien and Schwartz 1982).  We assume an innovating 
firm seeks external financing (i.e. capital) as an input to the production process.  The production 
process generates ideas and knowledge (i.e. human capital, innovations, etc.) which leads to 
development of revenue-generating output (i.e. physical products, intellectual products or services).  
However, the success in developing a revenue-generating output is uncertain, a priori.  In this sense, 
the firm could be viewed as determining the expected profit maximizing level of capital investment.  
Such an approach leads to an optimality condition for investment which equates the expected 
marginal value product of investment in research and development/innovation (i.e. the firm’s 
derived demand for capital raised via financing) to the (marginal) cost of capital (i.e. the supply of 
capital).   
  We can represent this notion by assuming firms behave as though they seek to maximize 
expected profits by choosing a level of investment in innovation/commercialization activities and 
that these activities lead to revenue generating output.  For clarity, we abstract away from dynamics 
and note that profits could be measured in period t as the discounted value of expected future 
profits.
i  We also assume that the firm only seeks outside investment, that is it does not utilize 
internal financing.
ii  Moreover, capital investment is assumed to be complementary with respect to 
other inputs and characteristics of the firm.  This behavioural model can be expressed as: 
   7
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where  π is (expected) profit, E[ ] is the expectation operator, P is price of output (either a product 
or process), output is produced via a production function, f( ), which depends on the level of capital, 
and capital is interacted with the function  ) , ( ψ z Q , where Q is a vector of firm specific exogenous 
factors and z is the vector of other factors of production, which are assumed fixed.  The interaction 
of capital with  ) , ( ψ z Q  reflects the notion that the unique combination of these other factors and 
inputs within each firm affects the marginal productivity of capital within each firm.
iii  The second to 
last element in (1) represents to cost of capital, where r is the rental rate and k is the level of capital, 
while the last element shows the value of other inputs (i.e. the inner product of the vector of input 
prices, w′, and vector of other inputs, z) to the production process.   
  For simplicity, we assume that only revenue is uncertain.  In this case, the Lagrange function 
associated with (1) is: 
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Equation (1’) leads to the following Kuhn-Tucker conditions: 
0 = λ - - ) ) , ( ψ ( r Pf E k z Q .          ( 2 a )  
0 ≥ λ ,  0 ≥ k ,  0 = λk .           ( 2 b )  
 
where  k f  is the marginal physical product of capital.  Assuming an interior solution (i.e.  0 = λ ), 
equation (2a) equates the expected marginal value product of capital in the production of an   8
innovation based product/process to the marginal cost of capital. Firms will demand capital up to 
the point where the expected marginal benefits equal the marginal cost of capital.  Moreover, the 
expected marginal benefits reflect the firm’s marginal productivity of capital and the firm’s inherent 
capacity to develop and commercialize innovations, as reflected by the interaction of capital with the 
function ) , ( ψ z Q .  Equation (2a) suggests that firms have a derived demand for capital investment: 
) , , | , ( = z Q Θ P r g k , where derived demand for capital is conditioned on the vector, Θ, which 
reflects parameters in f( ),  ) ( ψ  and the expectation process, as well as Q and z. 
  Derived demand for capital manifests itself via business plans and proposals presented to 
external financiers.  Experience and observation of the marketplace tells us that such business plans 
and proposals are complex and reflect much more than the expected marginal value product.   
Indeed, characteristics of the firm, its capabilities, partnerships, experience and overall scope for 
success will all be articulated in these proposals.  In this respect, the parameter vector Θ also 
reflects these firm based characteristics.  Moreover, such derived demands will have a choke price 
(or choke interest rate) at which the firm would choose not to seek external financing.  Both panels 
in Figure 1 illustrate the notion of derived demand for capital with a choke price denoted by c.  This 
figure assumes the production function is well behaved with respect to the level of capital.   
  Assuming firms are price takers in capital markets, then they will face a perfectly elastic supply 
of capital.  The latter is illustrated in panel 1a of figure 1 with a horizontal line at the interest rate r. 
A firm with derived demand for capital denoted  ) , , | , (
-1 z Q Θ P k g  and facing interest rate (or capital 
cost) r, will have an optimal level of capital investment k*.  Note, however, that if  r c < λ - , for a 
non-zero  λ, then a corner solution will result.  Panel 1a in figure 1 illustrates the impact of a non-
zero Lagrange multiplier via the downward shift in the inverse derived demand by an amount equal 
to λ, with the result being an optimal level of capital investment equal to zero.   9
  Recognize also that financiers fund projects based on a myriad of factors.  Examples of factors 
influencing a financing decision include market size, technology used, perceived probability of 
success, time to market, cost to market, the management team, and other factors such as firm 
resources, size and other revenue streams.  Because of the role these other factors play, financiers 
will often ration capital made available to firms based on an assessment of the likely success of the 
project/firm being funded.  This assessment will often lead to a risk premium being added to the 
risk free interest rate.  Such an outcome is illustrated in panel 1b in figure 1, where a risk premium, 
δ, has been added to the risk free rate to arrive at a risk adjusted interest rate, r′.  In this case, the 
level of investment, denoted k**, is not optimal (from the firm’s perspective), but it is not zero 
either.  It is important to recognize that the adjustment factor, δ, reflects the financier’s perception 
of the firm, and specifically, the financier’s perception of the firm’s marginal physical product of 
capital invested in innovation.  Given the scope of demand for capital investment, and time 
financiers devote to scrutinizing firms and knowledge they possess, the adjustment likely reflects the 
characteristics of the firm more so than the characteristics of the financier.  Also recognize that in an 
extreme case, the risk premium may be such that the firm would choose not to seek (accept) capital 
investment from the financier (i.e. a corner solution results).   
  Regardless of the case, the resulting level of investment will depend on a number of exogenous 
factors.  Clearly, factors exogenous to the firm and the financier will play a role.  However, given the 
many different sources of external financing, and the relatively large amounts of capital that are 
generally available, we assume that the supply of capital is perfectly elastic.  Such a view is entirely 
consistent with the notion of a threshold level of return required by financiers, as well as the fact 
that many different sources of financing exist.  As such, the factors driving access to, and obtaining 
of, investment funds (i.e. capital) reflect the characteristics of the firm seeking such funds.
iv  
Assuming a perfectly elastic supply of capital allows us to formulate a reduced form model relating   10
the decision to seek investment (or the level of capital obtained) in terms of factors specific to the 
firm seeking funds.  Moreover, given the arguments made about how δ reflects firm characteristics, 
then assuming the level of capital investment reflects characteristics of the firm seems reasonable.  
Firms with characteristics which prove useful in demonstrating scope for potential success will gain 
access to funds.   
  The literature is replete with studies examining the factors influencing research and 
development and innovation financing (see Hall 2002; 2005 for a recent discussion).  However, 
much of the previous work in this area has focused on the role of financial and liquidity constraints.  
Yet, other factors are also surely important.  In this regard we note that the literature is relatively 
silent in terms of explaining other factors which might influence which firms seek capital and, in 
turn, what influences how much capital is actually received.  In the context of the conceptual model 
above, the first issue, whether a firm seeks capital, relates to whether  ) , , | , ( >
1 - z Q Θ P k g r , while the 
second issue, how much does a firm receive, relates to solution of  ) , , | , ( =
1 - z Q Θ P k g r .  Our 
empirical model directly captures these two notions using a discrete event model and a two-step 
estimation procedure, respectively.  We conjecture that a firm’s chance of accessing capital, and the 
amount of capital received, is influenced by a variety of observable and measurable firm and sector-
specific characteristics.  These characteristics reflect: firm size and the intensity of involvement in 
the functional food and nutraceutical sector; prospects for business expansion; types of activities 
related to development/commercialization undertaken by the firm; firm ownership structure; 
distribution channels utilized by the firm; business practices of the firm; and the disease focus of 
functional foods and/or nutraceuticals produced by the firm.  
  Firm size has been found to be an important driver of the intensity of firm innovation (see for 
example Traore 2004; van Moorsel 2005).  The rationale for including firm size here relates to the 
fact that larger firms may be better able to spread research and development costs over more   11
projects, in turn facing lower capital requirements per unit of innovative output and requiring less 
external financing.  As well, larger firms may be better suited to self-financing, which again would 
lower the need for external sources of capital.  Moreover, firm size (i.e. an increase in firm size) 
could affect the marginal product of capital, possibly affecting the attractiveness of investment to a 
financier.  Smaller firms may require external financing as a means of remaining viable as their 
capital burn rate is typically proportionately greater than for larger firm, while smaller firm’s may 
have no (or little) revenue from which to finance innovation.  Regardless, scope exists for an inverse 
relationship between firm size and capital requirements through external sources.  On the other 
hand, larger firms, with more resource requirements, could face more stringent financial or liquidity 
constraints and therefore require additional outside financing.   
  A firm’s intensity of involvement in the functional food and nutraceutical sector and prospects 
for business expansion are included to reflect the positioning of the firm and their scope for future 
growth.  The functional food and nutraceutical sector is growing at a fast rate (Nutrition Business 
Journal 2004).  Large sectoral growth rates might give financiers cause to view firms in that sector 
more favorably when the firm seeks funds.  Intensity is included to reflect that some firms in the 
sector devote themselves to developing and marketing of functional foods and nutraceuticals only, 
while others view such products as complementary to their existing suite of products in other areas.  
Given growth in the sector, a firm which devotes a large amount of its resources to functional foods 
and nutraceuticals may be more like to receive capital (and possibly more capital) as it will “ride the 
growth” of the functional food and nutraceutical sector.  Prospects for business expansion reflect 
the same notion. 
  Van Moorsel et al. (2006) found positioning within the spectrum from product development to 
“goods on the market” is an important factor in shaping the innovative capacity of firms in the 
Canadian biotechnology sector.  In this regard, the types of activities a firm undertakes related to   12
functional food and nutraceutical product development and commercialization are included to 
reflect the firms’ relative position within the sector.  For instance, some firms position themselves in 
the development stage of the market, while other focus on commercialization (i.e. marketing) of 
products.  The capital requirements for functional food and nutraceutical product development are 
different from those needed for marketing such products.  Moreover, the nature of the market place 
in the various stages of the functional foods and nutraceuticals market differ; various market levels 
in the functional food and nutraceutical sector are more competitive than others, while others are 
more regulated.  Such differences may affect a firm’s propensity to obtain capital and, as such, are 
included here. 
  Various factors related to the firm are also included.  These include firm ownership structure, 
the distribution channels utilized by the firm and the firm’s business practices.  While largely driven 
by empirical consideration, many antecedents to this paper have found such factors to be important.  
Moreover, if policy is to be shaped in a way that better enables access to capital, understanding how 
these factors may (or may not) play a role could be useful.  Lastly, to reflect the fact that various 
disease states may offer more economically beneficial outcomes, the disease focus of the functional 
foods and/or nutraceuticals produced by the firm are also included.  The notion here is that a firm 
developing (or marketing) a product which addresses a widespread and/or severe disease states may 




The previous section outlined an approach to conceptualizing circumstances in which a firm would 
seek capital and the amount of capital they obtain if they seek capital.  Our empirical analysis 
considers these issues with two separate models.  In the first instance we develop a discrete event   13
model which relates the decision to seek capital to the factors discussed above.  We then develop a 
two-step model to aid in the determination of factors which influence the amount of capital 
investment a capital seeking firm receives.   
The former is accomplished by modeling the probability of the event that the firm seeks 
capital via a latent model.  In particular, we define an index function  i i i r P k g Y - ) , , | , ( =
1 - * z Q Θ  and 
write  1 = i Y  if  0 ≤
*
i Y  (in which case the firm seeks capital) and  0 = i Y  if  0 >
*
i Y  (in which case 
the firm does not seek capital), where the index i denotes observations.  Clearly, the latent variable, 
*
i Y , relates directly to the Lagrange multiplier (to see this note that the latent variable equals the 
same term as the Lagrange multiplier in (2a), namely  r P k g - ) , , | , (
1 - z Q Θ ).  We re-specify the index 
function as  i i Y ε + =
* β Xi , where  i X  is a vector of exogenous factors, β is a vector of unobserved 
parameters and  i ε  is an error term reflecting, among other things, errors in optimization and 
unobservable factors influencing the decision to seek (or not seek) capital.  It is assumed that the 
probability of a given firm making a choice to be a “seeker” or “non-seeker” is a function of these 
characteristics.  Therefore, the probability of a given firm choosing to raise capital can be 
characterized using the following: 
 
) 0 > ε + Pr( = ) 0 = Pr( i i Y β Xi  (3) 
) 0 ≤ ε + Pr( = ) 1 = Pr( i i Y β Xi  (4) 
 
Since equations (3) and (4) capture all probabilities of the random variable  i ε , such probabilities can 
be characterized by a cumulative probability density function (Davidson and MacKinnon 1993).  A 
cumulative normal density function is used to characterize  i ε , in which case the probability model   14
represented in (3) and (4) is a bivariate probit model.  Once the parameters of the model are 
estimated, it is possible to compute probability of an individual firm not-seeking capital (Pr(Yi=0)) 
and seeking capital (Pr(Yi=1)), as well as the marginal effects (i.e. change in the probability of 
seeking or not-seeking financing) arising from changes in the explanatory variables. 
  While capital-seeking is an interesting issue influencing innovation and commercialization in 
the functional food and nutraceutical sector, the amount of capital received by firms is perhaps a 
more important issue.  Thus, we also explore the factors influencing the amount of capital received 
by firms in the functional food and nutraceutical sector.
v  Note, however, that the decision to seek 
or not seek capital is not a random outcome within the sample; “capital seeker” and “capital non-
seeker” status is unlikely to be a random outcome, with important systematic differences between 
these two groups.  Firms who received zero capital may have a systematic association with certain 
firm characteristics if such zero capital outcomes are due to “non-seeker” status.  Thus, the amount 
of capital received by “capital seekers” may not, in general, provide a reliable estimate of what 
“capital non-seekers” would have received had they decided to raise capital. 
  The capital-seeking decision-making process is thus sequential, where the dichotomous 
outcome (seeker or non-seeker) is followed by a continuous outcome (the amount of capital 
received).  The Heckman two-step approach (Heckman, 1976) has been extensively used in 
estimating such dichotomous-continuous models.  In this procedure, a probit model, reflecting the 
dichotomous decision, is estimated in the first stage and a regression equation with a continuous 
non-zero dependent variable is estimated in the second.  Suppose the amount of capital raised (a 
dependent variable of continuous outcome) is dollar.  We assume that the firm’s derived demand for 
capital can be represented via the following: 
 
i i dollar ε + = ζ Xi            ( 5 )    15
 
However, this dependent variable is only observable for firms who choose to seek capital, with the 
decision to seek capital represented by the following relationship: 
 
i i u + = Λ
* γ Wi             ( 6 )  
 
where 
* Λi   is a latent variable,  i W  is a 1xm vector of explanatory variables, γ  is a mx1 vector of 
unobservable parameters, and dollar will be observed only when  0 > Λ
*
i .   In light of this, expected 
amount of capital raised, given that a firm seeks to raise capital, is given by equation (7): 
 
E(dollari|dollari observed)  =  ] 0 > Λ | [
*
i i dollar E  (7) 
 =  ] - > | [ i Wγ i i u dollar E  (8) 
 = ] - > | ε [ + i i Wγ ζ X i i u E  (9) 
 
Assuming ui  and εi have a bivariate normal distribution with zero means and correlation ρ , then (9) 
can be written as: 
 
E(dollari|dollari observed)=  i λ ρσ + ε ζ Xi  (10)   
 
where  i λ  is the inverse Mills ratio from the probit estimate of the dichotomous outcome (see 
Greene 2003 for details).Inclusion of the Mills ratio controls for the sequential decision making 
process (i.e. controls for sample selection issues in our dichotomous-continuous outcome), and   16
permits the role that factors in  i X  play in shaping the amount of capital received to be recovered.  
We use the maximum likelihood method with Heckman’s two step estimation procedure to estimate 
γ  for the dichotomous process and ζ  for the continuous process. 
 
Data and variables 
Data for this analysis was obtained from a 2003 survey of the functional food and nutraceutical 
sector (FFNS survey) conducted by the Small Business and Special Survey Division of Statistics 
Canada on behalf of  Agriculture and Agri-Food Canada.  The sample frame was developed using 
firms who had indicated that they are engaged in activities related to functional foods and 
nutraceuticals activities in the Biotechnology Use and Development Survey (BUDS) undertaken in 
2001.  The sample frame included 576 firms, of which 146 indicated that they were still engaged in 
activities related to functional food and nutraceutical sector (Table 1).  Of these 146 firms, 78 self-
identified as having activities exclusively related to nutraceuticals, 27 firms self-identified as having 
activities exclusively related to functional foods, 26 firms indicated activities in both sectors, and 15 
firms are engaged in other activities related to functional foods and nutraceuticals that are not 
related to the six activities listed in Table 1. 
 
TABLE 1 HERE 
 
Through preliminary analysis of the FFNS data, the seven groups of firm characteristics 
discussed in the conceptual framework were selected as explanatory variables for the attpt (attempt 
to raise capital) and dollar (amount of capital raised) models.  Descriptive statistics for each group of 
explanatory variables are reported in Table 2.  We assert that these characteristics distinguish firms 
in a manner that empirically-useful inferences can be derived through the analysis.  As will be seen,   17
firm size plays an important role in this analysis and so we also split out the means of the data 
according to firm size (defined as the number of employees).   
 
TABLE 2 HERE 
 
In the analysis, firm size (size) and intensity of involvement in the functional food and 
nutraceutical sector intensity (ffnint) is derived based on the total number of employees and the 
number of employees who are engaged in activities specifically related to functional foods and 
nutraceuticals.  Firm size is based on the total number of employees in 2002, including permanent 
and seasonal/casual/contract employees.  Average firm size is 492 employees (with a standard 
deviation  of 2,850) with substantial variation within the sample.  One might expect firm size to be 
inversely related to the chance of seeking capital, the notion being that larger firms have access to 
capital reserves via internal financing.  However, one might also expect that smaller, capital seeking 
firms obtain less capital as their size diminishes the need for capital compared to larger firms.  The 
ratio of employees engaged in activities directly related to functional foods and nutraceuticals to total 
employees is used as a measure of intensity of involvement in the functional food and nutraceutical 
sector (ffnint).  The sample average of measured intensity is 64.3 percent, but varies across firm size, 
with smaller firms being more intensely focused on functional foods and nutraceuticals.  Intensity is 
expected to be positively related to both the probability that a firm seeks capital and the amount of 
capital obtained.  The premise here is that firms which are intensely engaged in functional food and 
nutraceutical development are more likely to have a high choke price (reflecting large development 
costs), thus raising the chance of an interior solution and the optimal amount of capital a firm 
obtains.   18
  The prospect for a firm to expand its business is measured in terms of the number of new 
hirings (inboom) and the number of unfilled vacancies (unfill) in 2002 with respect to activities directly 
related to functional foods and nutraceuticals.   These variables are included as both the number of 
new hirings and unfilled positions will reflect the anticipated human capital needs of the firms.  Our 
contention is that such anticipated capacity is a measure of the potential for business expansion 
(and, following Spence (1977) and Dixit (1980) may carry with it strategic implications related to 
human capital capacity which make the firm more appealing to potential investors).  Both variables 
are expected to have a positive influence on the probability of a firm seeking capital and the amount 
of capital obtained.  Firms with greater growth potential are more likely to be viewed positively by 
financiers.  As well, firms with a larger number of recent new hires and unfilled positions are likely 
to be undertaking more development relative to firms without new hires and unfilled positions.  
This could be reflected in an upwards shift in the derived demand for capital, thus raising the chance 
that the firm will seek capital and the amount of capital received by the firm.  Note that inboom 
increases in firm size, while unfill falls in firm size. 
The firm’s activities related to the development and/or commercialization of functional 
foods and nutraceuticals is characterized using six dummy variables related to participation in 
research and development (rd), product development/scale up (prdev), ingredient manufacture (igmfg), 
manufacture of consumer-ready products (crdyp), wholesaling (whole), and retailing (retail).  Around 65 
percent of the firms are involved in product development and scaling-up, but only around 26 
percent in retailing.  Our expectation is that firms involved in activities related to the early stage of 
the development to on-the-market continuum (e.g. research and development, product 
development/scale-up) are more likely to seek capital and have higher capital needs compared to 
firms involved in the distribution and marketing of functional foods and nutraceuticals.    19
  The ownership structure of firms was represented with five dummy variables.  Around 86 
percent of the firms are Canadian owned (cnd) and about 72 percent are private corporations (pvt).   
Relatively few (about 11 percent) are multinationals (multina) or public corporations (pubco), while 
around nine percent are unincorporated partnership (ptshp).  We do not have strong sign 
expectations for Canadian ownership, but would expect multinationals and public corporations to 
have less need for capital.  The notion here is that such firms have access to other forms of capital, 
either through a parent company or via IPO/stock offerings, thus suggesting a negative effect in 
both empirical models.  Privately owned firms and partnerships, which often have limited amounts 
of capital, are more likely to have greater need for capital, which suggests a positive effect of these 
variables, both on the probability of seeking financing and the amount received.   
The three main distribution channels used by the firms are direct sales to customers (direct), 
sales through retailers/wholesalers (rtwh) and exporting (export).  Approximately, 54 percent of the 
firms were engage in exporting, while 44 percent sold direct to consumers through the internet or 
mail order.  The expected effect of these variables are uncertain and largely an empirical issue. 
   In the analysis, a distinction is made between five business practices, namely whether the 
firm is in a partnership (partner), whether the firm has contracted out functional food and 
nutraceutical-related activities (contrac), whether intellectual property rights (IPRs) have been granted 
to other firms (grtipr), whether intellectual property rights have been acquired from other firms 
(aqipr), and the number of existing and pending patents belonging to the firm (patents).  
Approximately 37 percent of firms had engaged in a partnership, while 40 percent had contracted-
out functional food and nutraceutical-related activities.  Significantly more firms had acquired 
intellectual property rights from other firms (17%) than had granted such rights to other firms (5%).  
Broadly speaking these variables reflect networking and information sharing of the firm with other 
firms/agencies.  One might expect that firms engaged in activities which involve little/no   20
expenditure or scope for raising revenue (i.e. partnerships and granting of IPRs) will have less 
demand for capital, either because expertise/knowledge is garnered via the partnership or because 
granting of IPRs is a source of revenue which can be used to finance innovation activities.  On the 
other hand, involvement in partnerships and granting of IPRs could reflect a great deal of 
innovation activity by the firm, thus suggesting a positive effect of these variables.  Involvement in 
activities which involved the expenditure of capital (i.e. acquiring IPRs, contracting out activities and 
development of patents) would raise capital demands, thus suggesting a positive effect of these 
variables.  However, firms which undertake these activities, especially acquiring IPRs and 
contracting, may do so because they lack the expertise and capacity needed to successfully execute 
these activities.  In this sense, purchasing IPRs and contracting out functional food and nutraceutical 
activities could be a least cost solution for many firms, and reflect less need for capital.  In this 
instance, the variables aqipr and contrac are expected to have a negative  effect. Finally, seven dummy 
variables are used to characterize the diseases on which the functional foods and/or nutraceuticals 
of the firms focus.  The dummy variables have a value of one if the firm has product lines for more 
than one disease type (multipro), and if a firm has product lines for heart and vascular disease (heart), 
diabetes (diabet), cancer (cancer), gut health (gut), immune system conditions (immune) and bone health 
(bone).  Across the sample, 72 percent of firms have products that focus on more than one disease 
type.  The disease state for which the largest proportion (54%) of firms had products was heart and 
vascular disease.  Sign expectations for multipro are mix; firms with multiple product lines may face 
greater need for capital as existing resources become too thinly spread across product lines.  On the 
other hand, knowledge and innovation spillovers and economies of scope may actually reduce the 
need for capital of firms with multiple product lines.  The role of the disease state variables is 
uncertain and largely an empirical issue.   21
  Of the 146 firms responding to the FFNS survey, 45 firms (31%) had attempted to raise 
capital.  The majority of these firms reported product innovation and commercialization as the 
principle reason for attempting to raise capital from external sources (Figure 2).  Firms had sought 
financing through a variety of sources (Figure 3), mostly through commercial banks, Canadian 
venture capital and government.  The majority of firms raising capital had done so through 
commercial banks and were Canadian owned (86%) and private corporations (about 72%).  The 
average size of firms that had attempted to raise capital was 39 employees, while average size of 
firms not seeking external financing was 445 employees.  Moreover, the intensity of involvement in 
the functional food and nutraceutical sector among firms seeking capital was 80 percent, compared 
to 58 percent for firms not seeking external financing.  This suggests that smaller firms with a 
greater focus on the functional food and nutraceutical sector had a greater propensity to seek 
external financing for their innovation and commercialization activities (as illustrated in Table 2).  
Such a result is not unsurprising given the small scale of many of the start-up firms engaged in 
functional food and nutraceutical innovation and commercialization.  However, larger firms sought 
more capital compared to smaller firms (at least in total). 
 
Results of the Regression Analysis 
Probit Analysis of Seeking Capital 
The results of the probit regression on the dichotomous outcome of seeking finance (attpt) are 
reported in Table 3.  Overall, the regression model explains the dichotomous outcome of seeking 
capital reasonably well (the psuedo-R
2 is 0.44, which is relative high for cross-sectional data).  The 
Chi Square value for the goodness of fit test is significant with a p-value of 0.003.  As expected, an 
inverse relationship exists between size and the probability that a firm will seek capital.  In particular, 
the coefficient on this variable is negative and significant at the five percent significance level.  The   22
marginal probability for the size variable indicates that a one percent increase in firm size reduces 
the likelihood of a firm seeking capital by 0.0023 percent.
vi  Presumably, larger firms are more likely 
to have internal budgetary resources to enable self-financing and would not have to access external 
capital sources, suggesting at the outset that issues and problems associated with external finance are 
more an issue for SMEs. 
 
TABLE 3 HERE 
 
The estimated coefficient on ffnint is positive and significant at the one percent level.  Firms 
with a greater share of their business related to functional food and nutraceutical activities (ffnint) 
have a higher likelihood of seeking capital.  In particular, a one percent increase in the intensity of 
participation in the functional food and nutraceutical sector (ffnint) would increase the likelihood of a 
seeking external finance by 0.76 percent.  As expected, variables representing the firm’s prospects 
for expanding their business related to functional foods and nutraceuticals (i.e. inboom and unfill) have 
statistically significant and positive coefficient estimates.  Firms with a higher number of new hirings 
or with unfilled positions in the FFN sector are more likely to search for capital.  Moreover, the 
impact of potential for business expansion is not trivial in shaping the probability of seeking 
financing.  For instance, a one percent increase in the number of new hirings with responsibilities 
directly related to functional foods and nutraceuticals would increase the probability of seeking 
capital by 1.6 percent.  Indeed, many of the firms in this sector are new or very young firms, small in 
size and typically face internal financing constraints.  This highlights the crucial role played by the 
availability of external financing for the expansion of business activities in the functional food and 
nutraceutical sector.     23
  Interestingly, the various functions performed by the firms related to functional food and 
nutraceuticals had no significant impact on the propensity to seek capital.  As indicated above, one 
might expect firms engaged in research and development to have a greater likelihood of searching 
for capital; while the coefficient for the dummy corresponding to involvement in research and 
development (rd) is positive, it is not significant. 
  Firm ownership appears to play little role in shaping the likelihood that a firm will seek 
capital.  In fact, only the coefficient for the dummy variable pvt is significant (at the five percent 
level), and has a negative sign, in contrast to expectations.  Switching from any other ownership 
arrangement to being a private corporation would decrease the likelihood of seeking capital by 3.1 
percent.  Private ownership brings with it less need for external financing; privately owned firms in 
the sample appear to have sufficient levels of internal capital.  Canadian-owned firms have a greater 
propensity to searching for capital, yet the coefficient is not significant at the five percent level.   
  There are no systematic associations between distribution channels used by firms in the 
functional food and nutraceutical sector and the propensity to seek capital.  Although, the 
coefficients for direct and export were negative, they were not significant at the five percent level.  
However, among the business practices of firms in the functional food and nutraceutical sector, 
being in a partnership is positively associated, and significant, with the likelihood of seeking capital.  
Moreover, the likelihood of seeking capital would increase by about three percent if a firm is in a 
partnership relative to a firm which is not.  In this respect it is possible that the very purpose of 
forming a partnership is to secure access to external financing.  However, only about 14 percent of 
the firms in the FFNS reported that the purpose of their partnership was for accessing capital, while 
only eight percent of the firms who attempted to raise capital reported that the purpose of the 
partnership to which they belonged was to access capital.  Indeed, the major rationale for 
establishing a partnership was to conduct scientific research and development (36%), access   24
markets/distribution channels (28%) or production/manufacture (27%).  These results suggest that 
firms seek capital to access needed services that they are reluctant to undertake in-house, perhaps 
because of the lack of internal capabilities or economies of scope.  Or it may be that firms involved 
in partnerships are actively involved in development and require both financing and external 
knowledge to complete.  Moreover, it is important to note that the services being sought through 
partnerships could be viewed as an indirect means of accessing capital (either physical or human).  
The sign on the coefficient for the contrac variable is negative and significant at the five percent level.  
As discussed above, firms which can afford to contract out functional food and nutraceutical related 
activities do not suffer from a lack of capital and, therefore, do not seek capital. Nevertheless, firms 
with insufficient financial resources (and need external capital) are more likely to secure outside 
expertise through partnerships while those with more internal resources (and need less/no external 
capital) are more likely to hire necessary external capabilities. 
  Finally, there is no systematic association between the likelihood of seeking capital and the 
focus by firms on more than one disease state, nor the specific diseases on which the functional 
food and nutraceutical firm’s focus.  None of the disease-state dummy variables had significant 
coefficients at the five percent level.  In retrospect, this is perhaps contrary to a priori expectations.  
For example, firms engaged in functional food and nutraceutical activities related to multiple 
diseases might be considered in greater need of external finance because of the scope of separable 
activities associated with products directed at different disease states. 
  
Heckman’s two stage approach for seeking capital and amount of capital raised 
The Heckman two step method, as outlined above, is used to explore the influence of variables on 
the amount of capital raised by the firms in the Canadian functional food and nutraceutical sector.  
The two-step method is generally sensitive to specifying a correct model (Stata 8).  Indeed, there   25
were collinearity problems when attempting to estimate the model which included all of the a priori 
variables, as specified in Table 2.  An added complication was that, out of 146 firms, only 26 firms 
reported non-zero values for the amount of capital raised.  Thus, through the estimation process, 
the least number of collinear variables were dropped and the model re-estimated.  In this process we 
strived to keep variables representing all of the seven variable groupings.  Nevertheless, the results 
must be interpreted with care. 
  In the Heckman two-step approach, the first stage is the probit estimation of the 
dichotomous outcome of the “seek”/“non-seek” decision.  This process is characterized by 
Equation 6, with regressors (Wi) taken from variables which are significant in the “seek” decision in 
Table 3, namely size, ffnint, unfill, inboom, pvt, partner, contrac.  Non-collinear variables explaining the 
dollar amount raised, (Xi) as characterized by Equation 5 are rd, prdev, export, size, ffnint, partner, contrac, 
grtipr, aqipr, patents and multipro.  The results are reported in Table 4.   
 
TABLE 4 HERE 
 
The error terms of the two processes (ui and εi of Equations 6 and 7) are perfectly correlated 
(ρ=-1) indicating that using OLS regression for the dollar amount received by these firms would 
result in be inconsistent estimates.  The Wald test of the null hypothesis that all coefficients are 
jointly equal to zero is rejected with Chi Square value of 40.76 and p-value of 0.0003.  The selection 
component of the Heckman procedure does not provide any additional information since all of 
these variables were taken from the previous probit model.  With the exception of ffnint and unfill, 
the estimated coefficients concord with the results of the probit regression reported in Table 3.  For 
the two variables with different coefficient signs (i.e. ffnint and unfill), the coefficient estimates are not 
statistically significant at the ten percent level.   26
  In the dollar amount raised model (i.e. the continuous portion of the dichotomous-
continuous decisions), coefficients on the variables rd and size are positive and significant at the ten 
and five percent, respectively.  When a firm is involved in research and development activities it 
needs more capital and is more likely to search with greater intensity for external funding, with the 
end result being a higher level of obtained capital.  Larger firms are more likely to raise greater 
amounts of capital since they have a larger equity base to act as collateral and may be considered 
lower risk, and may have greater capital requirements.  A one percent increase in firm size would 
increase the amount of capital raised by about C$11,000, if a firm decided to seek capital, while firms 
engaged in research and development raised C$1.7 million more than firms not engaged in research 
and development.  The coefficients for the variables prdev and ffnint are negative and significant at the 
five and one percent level, respectively.  The inverse relationship between level of capital obtained 
and prdev likely reflects the risks inherent in developing a new product and scaling-up production to 
a commercial level.  Financiers may be leery of funding unproven concepts, which would result in 
greater capital rationing to the firms engaged in product developing/scaling-up, hence the inverse 
relationship. 
  The negative and significant coefficient for the firm’s intensity of involvement in the 
functional food and nutraceutical sector suggests that, ceterius paribus, involvement in this sector 
decreases the amount of capital firms can raise.  This may reflect the novel nature of many of the 
products in this sector and the infancy of markets in this sector, making potential financers wary of 
making large investments in forms therein engaged.  Indeed, we might expect quite significant 
asymmetric information and moral hazard problems, especially where firms are reluctant to release 
information on innovative products at the developmental stage.    
  However, results related to ffnint do present a vexing dilemma for firms; firms with a high 
level of functional food and nutraceutical intensity are more likely to seek external financing, but   27
obtain less capital than a firm which has a lower level of functional food and nutraceutical intensity.  
This again may reflect capital rationing by financiers based on an uncertain future.  In particular, the 
functional food and nutraceutical sector is in its infancy.  While growth rates thus far have been 
strong, the future remains less certain.  As functional foods and nutraceuticals move through the 
product life cycle, growth rates will slow and returns will likely diminish.  As well, uncertainty with 
respect to the regulatory environment in Canada and abroad (i.e. in Canada’s export markets) may 
give financiers cause to discount anticipated rates of return to firms heavily engaged in this sector.  
Both of these factors may lead to capital rationing with respect to functional food and nutraceutical 
intensity firms, and hence the observed results. 
 The  variables  multipro, patents, grtipr and export have positive coefficients, while partner, contrac, 
and aqipr have negative coefficients, although none are significant at the five percent level.  Thus, 
these components of the model do not appear to provide any useful information to our analysis.  
Such result underscores the importance of the few significant variables in capturing firm’s demand 
for capital in Canada’s functional food and nutraceutical sector. 
 
Summary and Conclusion 
Growth in consumer interest in functional foods and nutraceuticals has been seen as a significant 
business opportunity for the agri-food sector in Canada.  As a result, the functional food and 
nutraceutical sector is expanding rapidly, although many of the new firms in the sector are SMEs 
and face typical difficulties obtaining financing for their innovation and commercialization activities.  
The aim of this paper is to understand better the factors which affect a firm’s decision to seek 
external financing and the level of financing obtained as a result. 
  The first aim is explored using a discrete choice analysis of the decision to seek external 
funding.  Results from this analysis indicate that smaller firms, firms organized as privately held   28
corporations and those which contract out functional food and nutraceutical activities are less likely 
to seek external funding.  However, firms which are more intensely involved in the functional food 
and nutraceutical sector, who have great prospects for business expansion and have been involved in 
a partnership are more likely to seek external financing.   
  The second aim is addressed by developing a sample-selection model where the choice to 
seek external financing is included in the first stage and the amount of funding to be obtained is 
included in the second stage.  Larger firms are less likely to raise capital through external sources, 
but received greater amounts of capital when they decided to raise capital.  Firms with a greater 
share of functional food and nutraceutical activities in their business are more likely to search for 
capital, but receive less capital than less intensive firms.  Often, such functional food and 
nutraceutical intensive firms are small start-up ventures.  Our finding with respect to intensity not 
only highlights the importance of some public support for capital requirements for such firms, but 
also the additional burden on smaller functional food and nutraceutical intensive firms.  Smaller 
firms encounter more difficulties accessing capital.  The role of the firm in the functional food and 
nutraceutical development and commercialization process plays a role in the amount of funding 
obtained.  Firms engaged in pure research and development received more capital, while firms in the 
product development and scaling-up process received less capital compared to firms engaged in 
other activities.  This suggests that financiers may ration capital on a differential basis according to 
the firm’s role.  Alternatively, research and development based firms may have higher capital 
requirements and therefore seek, and obtain, access to larger amounts of capital, while product 
development and scale-up based firms have lower capital requirements and therefore seek less 
money.   
  The conceptual literature suggests that information asymmetry, the non-rival nature of 
knowledge, liquidity constraints and lack of collateral are reasons why there is under-investment in   29
research and development and innovation (see for example Hall 2002; 2005).  Moreover, these 
factors often underlie calls for government programs which enable firms to access capital for 
research and development and innovation.  If such under-investment has occurred, then a natural 
question to ask is how do the results reported here aid in the development or shaping of policies and 
programs which might enable greater access to capital.  We maintain that two key points stand out.  
First, such policies ought to be targeted to smaller firms.  These firms are more likely to seek 
external financing, potentially demonstrating a greater unsatisfied need, but receive less capital than 
larger firms.  Second, consideration ought to be given to directing access to capital to firms which 
are more specialized in the functional food and nutraceutical sector (i.e. the functional food and 
nutraceutical intensive firms).  The latter firms are more likely to seek capital (again demonstrating a 
potential need), but receive less capital than firms which are more diversified.  Given the scope for 
regulatory impediments to future growth opportunities in the functional food and nutraceutical 
sector, firms which specialize may be viewed by financiers as more risky precisely because of 
regulatory uncertainty at home and abroad.  Despite the growth and scope for opportunity in this 
sector, the anticipated returns to firms which specialize in functional foods and/or nutraceuticals 
may be discounted due to the regulatory environment, the result being under-investment (or no 
investment).  Since this under-investment stems from deficiencies in the regulatory environment, 
one could argue that not only do these deficiencies need to be addressed, but capital access 
programs could also be designed to facilitate socially optimal investment during the transition to a 
new regulatory environment.   30
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Table 1.  Number of firms across activities in the Canadian functional foods and 
nutraceuticals sector 
Sector Number  of 
firms  
Nutraceutical activities only  78 
Nutraceuticals that are extracted or purified from plants (for example beta-
glucan from oats, antioxidants from blueberries, isoflavanoids from soy, 
sterols from wood pulp, essential fatty acids from primrose oil, soluble fiber 
from fenugreek, etc.) 
 
64 
Nutraceuticals that are ground, dried, powdered, and pressed from plant 




Nutraceuticals that are produced extracted or purified from animals and 




Nutraceuticals that are produced, extracted or purified from marine sources 
(for example. Glucosamine, chitosan, products from algae, seaweed, kelp, 
fish oils, etc)  
53 
Functional food activities only  27 
Foods that have added active ingredients other than vitamins or minerals 
and have been scientifically demonstrated to provide health benefits beyond 
their basic nutritional functions (for example Muffins with beta-glucan, 
drinks with herb blends, foods with added soluble fibre, etc.) 
 
63 
Foods specially enhanced to contain more of a functional component, 
through plant breeding techniques, genetic modification, processing, or 
special live stock feeding techniques, that have been scientifically 
demonstrated to provide health benefits beyond their basic nutritional 
functions (for example tomato with enhanced lycopene level, canola high in 
carotenoids, strawberries containing increase levels of ellagic acid, omega-3 
eggs, etc.) 
20 
Firm in both functional food and nutraceutical activities  26 
Other Activities (not related to above 6 but other FFN related activities)  15 
Total Number of Firms  146   34
Table 2. Description of explanatory variables 










Name Description Type  Mean Std  Dev. Mean  Mean  Mean 
  Dependent variables         
attpt=1  If firm attempted to raise capital in 2002 otherwise zero  dummy  0.315 0.466 0.347 0.292 0.208 
dollar  Amount of capital received by a firm requesting capital (in dollars)  scale  1247462  2610639 343172  468000 4801500 
  Independent variables         
  Firm Size and Involvement in Functional Foods and Nutraceutical Sector            
size  Number of all employees of the firm (in 2002)  integer  491.628 2850.137  12.521  78.348  2626.231 
ffnint  Number of employee in FFN activities/Total Employees  ratio  0.640 0.407 0.769 0.504 0.280 
  Prospects for Business Expansion         
inboom  Number of new hirings in 2002 for FFN  activities   integer  1.946 5.032 1.000 2.217 5.363 
unfill=1  If firm has currently unfilled positions for FFN activities  dummy  0.229 0.422 0.260 0.174 0.160 
  Activities         
rd=1  If firm participate in R & D activities otherwise zero  dummy  0.534 0.501 0.510 0.667 0.500 
prdev=1  If firm participate in product development/scale up otherwise zero  dummy  0.651 0.478 0.573 0.958 0.654 
igmfg=1  If firm manufacture ingredients otherwise zero  dummy  0.274 0.448 0.292 0.292 0.192 
crdyp=1   If firm manufacture consumer ready products otherwise zero  dummy  0.562 0.498 0.521 0.583 0.692 
whole=1  If firm is a wholesaler of products otherwise zero  dummy  0.479 0.501 0.562 0.375 0.269 
retail =1  If firm is a retailer of products otherwise zero  dummy  0.260 0.440 0.271 0.334 0.154 
  Business Ownership         
multina=1  If firm is a multinational otherwise zero  dummy  0.116 0.322 0.084 0.084 0.270 
pvt=1   If firm is a private corporation otherwise zero  dummy  0.719 0.451 0.781 0.750 0.466 
pubco=1  If firm is a public corporation otherwise zero   dummy  0.110 0.313 0.083 0.042 0.270 
ptshp=1  If firm is a unincorporated partnership otherwise zero  dummy  0.089 0.286 0.114 0.083 0.000 
cnd=1  If firm ownership is Canadian (excluded foreign) otherwise zero  dummy  0.856 0.352 0.917 0.834 0.654 
  Distribution Channels         
direct=1  If firm sells to customers directly   dummy  0.438 0.498 0.510 0.334 0.270 
rtwh=1   If firm sells through retailers/wholesalers  dummy  0.692 0.463 0.708 0.625 0.692 
export=1  If firm is an exporter (excluded non-exporting)  dummy  0.541 0.500 0.573 0.625 0.346 
  Business Practices         
partner=1  If firm has been in a partnership  dummy  0.375 0.486 0.330 0.375 0.538 
contrac=1  If firm has contracted out functional foods and nutraceutical activities  dummy  0.396 0.491  0.4176  0.434 0.280 
grtipr=1  If firm has granted intellectual property rights to other firms  dummy  0.049 0.217 0.053 0.043 0.040   35
aqipr=1  If firm has acquired intellectual property rights from other firms  dummy  0.169 0.376 0.189 0.095 0.160 
patents  Number of existing and pending patents   integer  1.315 6.494 1.740 0.792 0.231 
  Disease Focus of Products         
multipro=1  If firm has products lines for more than one disease status  dummy  0.719 0.451 0.677 0.834 0.770 
heart=1  If firm has products lines for vascular and heart health   dummy  0.541 0.500 0.500 0.625 0.615 
diabet=1  If firm has product lines for diabetes   dummy  0.363 0.483 0.375 0.417 0.269 
cancer=1  If firm has product lines for cancer  dummy  0.329 0.471 0.344 0.250 0.346 
gut=1  If firm has product lines for gut health  dummy  0.390 0.490 0.323 0.541 0.500 
immun=1  If firm has product lines for immune system  dummy  0.466 0.501 0.458 0.625 0.346 
bone=1  If firm has product lines for bone health  dummy  0.349 0.478 0.292 0.417 0.500 
a. Small firms have less than 50 employees, medium firms have between 50 and 149 employees, larger firms have 150 employees or more.  36
Table 3. Regression results for probit analysis of ‘seeking capital’ decision 
Name Description  Coefficent  P-value 
marginal 
probability % 
Cons Regression  Constant  -2.005439 0.115   
  Firm Size and Involvement in Functional Foods and Nutraceutical Sector      
size  Number of all employees of the firm (in 2002)  -0.0061166  0.012**  -0.00229 
ffnint  Number of employee in FFN activities/Total Employees  2.03415  0.006***  0.76197 
  Prospects for Business Expansion      
inboom  Number of employees hired in 2002 for FFN  activities   1.221267  0.015**  1.61426 
unfill=1  If firm has currently unfilled positions for FFN activities  0.1224831  0.029**  0.04588 
  Activities      
rd=1  If firm participate in R & D activities otherwise zero  0.5288859  0.271   
prdev=1  If firm participate in product development/scale up otherwise zero  -0.1799914  0.75   
igmfg=1  If firm manufacture ingredients otherwise zero  -0.7358607  0.184   
crdyp=1   If firm manufacture consumer ready products otherwise zero  0.2109186  0.643   
whole=1  If firm is a wholesaler of products otherwise zero  0.0355694  0.946   
retail =1  If firm is a retailer of products otherwise zero  0.6609096  0.276   
  Business Ownership      
multina=1  If firm is a multinational otherwise zero  -1.912661  0.105   
pvt=1   If firm is a private corporation otherwise zero  -1.678879  0.049**  -3.1028 
pubco=1  If firm is a public corporation otherwise zero   -0.5358424  0.624   
ptshp=1  If firm is a unincorporated partnership otherwise zero  -1.192045  0.208   
cnd=1  If firm ownership is Canadian (excluded foreign) otherwise zero  1.297047  0.205   
  Distribution Channels      
direct=1  If firm sells to customers directly   -0.2153158  0.676   
rtwh=1   If firm sells through retailers/wholesalers  0.4506189  0.388   
export=1  If firm is an exporter (excluded non-exporting)  -0.7356804  0.156   
  Business Practices      
partner=1  If firm has been in a partnership  1.92333  0.001***  3.19894 
contrac=1  If firm has contracted out FFN activities  -1.139688  0.039**  -0.46018 
grtipr=1  If firm has granted intellectual property rights to other firms  0.7066242  0.486   
aqipr=1  If firm has acquired intellectual property rights from other firms  -0.0985204  0.857   
patents  Number of existing and pending patents   0.0405107  0.202   
  Disease Focus of Products      
multipro=1  If firm has products lines for more than one disease status  -0.1637227  0.737   
heart=1  If firm has products lines for vascular and heart health   -0.096356  0.855   
diabet=1  If firm has product lines for diabetes   0.0108554  0.987   
cancer=1  If firm has product lines for cancer  -0.6116602  0.23   
gut=1  If firm has product lines for gut health  0.0348286  0.958   
immun=1  If firm has product lines for immune system  0.5512856  0.373   
bone=1  If firm has product lines for bone health  -0.6875929  0.233    
Number of observations = 107 
Log likelihood =  -37.70755 
Pseudo R
2     = 0.4425 
Log Likelihood Ratio Test chi square 2(30) =  59.86 
*** Significant at the one percent level 
** Significant at the five percent level   37
Table 4. Regression results for Heckman two-step method 
Variable   Coefficient  p-value 
Select    
constant  -1.13986 0.015
** 
size  -0.0029 0.08
* 
ffnint  0.546596 0.277 
unfill  0.273239 0.426 
inboom  0.100671 0.004
*** 
pvt  -0.83798 0.025
** 
partner  0.728806 0.05
** 
contrac  -0.11523 0.739 
    
Dollar    
constant 7846453  0.003
*** 
Rd 1650107  0.086
* 
prdev -2653396  0.028
** 
export 997359.4  0.295 
Size 10971.21  0.017
** 
ffnint -4562925  0.003
*** 
partner -1568823  0.139 
contrac -1142717  0.256 
grtipr 1076597  0.409 
Aqipr -563971  0.733 
patents 7498.192  0.841 
multipro 1375927 0.196 
Number of observations 118 
Wald test chi square (2, 15)= 40.76 (p=0.0003) 
*** Significant at the one percent level 
** Significant at the five percent level 
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Figure 1. Reasons for attempting to raise capital among Canadian firms in functional foods 
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Figure 2. Sources of capital for firms in the Canadian functional foods and nutraceuticals 
sector   40
End Notes 
                                                 
i Murphy et al. (1993) invoked a similar assumption when assessing the gains from agricultural 
research with distorted trade.  
ii This assumption could be relaxed, but would require additional structure which differentiates 
between internal and external financing and adds a mechanism by which internal financing is 
achieved via capital structure.  As such detail is not required for our simple analytical model, we have 
chosen not to incorporate internal/external financing decisions. 
iii This approach reflects the notion that the marginal productivity of capital can be enhanced via 
factors specific to the firm.  In some respects, such a view has roots in contemporary growth theory 
based models (especially endogenous growth theory), wherein the ideas, people and technology 
within the firm drive its innovations and output (see Aghion and Howitt 1997, for example).  
 
iv We recognize that the nature of the financier may also play a role.  For instance, different 
financiers may have different thresholds.  However, it could be argued that such differences will be 
eroded via competition in the capital market, such that individual thresholds converge on a common 
threshold (perhaps with slight adjustment for risk). 
v Here we model the amount of capital a firm is successful in raising, given that they were a capital 
seeker.  This amount, however, may have been less than the quantity of capital the firm was 
attempting to raise, which we do not address here. 
vi For sake of brevity, we only report marginal effects for the statistically significant variables. 